6533b839fe1ef96bd12a644f

RESEARCH PRODUCT

Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers.

Carmen Peña-bautistaAna García BlancoJean-marie GalanoCamille OgerConsuelo Cháfer-pericásMáximo VentoNuria Martín-ibáñezThierry DurandMiguel BaqueroClaire Vigor

subject

0301 basic medicineAnalyteLipid peroxidationUrineUrineIsoprostanesAnalytical ChemistryLipid peroxidation03 medical and health scienceschemistry.chemical_compoundIsoprostaneAlzheimer DiseaseTandem Mass SpectrometrymedicineHumansNeuroprostanesCognitive impairmentFuransChromatography High Pressure LiquidDetection limitChromatographyMass spectrometryIsofuranBiomarkerReceptors Prostaglandin E EP2 Subtypemedicine.disease030104 developmental biologychemistryPotential biomarkers[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]NeuroprostanesLipid PeroxidationNeurological damageAlzheimer's disease[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkers

description

Lipid peroxidation plays an important role in Alzheimer Disease, so corresponding metabolites found in urine samples could be potential biomarkers. The aim of this work is to develop a reliable ultra-performance liquid chromatography-tandem mass spectrometry analytical method to determine a new set of lipid peroxidation compounds in urine samples. Excellent sensitivity was achieved with limits of detection between 0.08 and 17 nmol L-1, which renders this method suitable to monitor analytes concentrations in real samples. The method's precision was satisfactory with coefficients of variation around 5-17% (infra-day) and 8-19% (inter-day). The accuracy of the method was assessed by analysis of spiked urine samples obtaining recoveries between 70% and 120% for most of the analytes. The utility of the described method was tested by analyzing urine samples from patients early diagnosed with mild cognitive impairment or mild dementia Alzheimer Disease following the clinical standard criteria. As preliminary results, some analytes (17(RS)-10-epi-SC-Delta(15)-11-dihomo-IsoF, PGE(2)) and total parameters (Neuroprostanes, Isoprostanes, Isofurans) show differences between the control and the clinical groups. So, these analytes could be potential early Alzheimer Disease biomarkers assessing the patients' pro-oxidant condition.

10.1016/j.talanta.2018.03.002https://pubmed.ncbi.nlm.nih.gov/29674032